Publications

Selected Recent Publications:

Czernin J, Current K, Mona CE,Nyiranshuti L, Hikmat F, Radu C, Lueckerath K. Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. JNM (accepted for publication, 06/2020)

Brouillette RL, Besserer-Offroy É, Mona CE, Chartier M, Lavenus S, Sousbie M, Belleville K, Longpré JM, Marsault É, Grandbois M, Sarret P. Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain.(Link is external) (Link opens in new window) Pharmacol Res. 2020 May;155:104750. doi: 10.1016/j.phrs.2020.104750. Epub 2020 Mar 6.PMID: 32151680

Stuparu AD, Meyer CAL, Evans-Axelsson SL, Lückerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.(Link is external) (Link opens in new window) 2020;10(6):2612-2620. doi: 10.7150/thno.42228. eCollection 2020. PubMed PMID: 32194823; PubMed Central PMCID: PMC7052903.

Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.(Link is external) (Link opens in new window) Clin Cancer Res. 2020 Jan 13;. doi: 10.1158/1078-0432.CCR-19-1485. [Epub ahead of print] PubMed PMID: 31932492; NIHMSID:NIHMS1549816.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.(Link is external) (Link opens in new window) EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z. PubMed PMID: 30374743; PubMed Central PMCID: PMC6206308.

Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.(Link is external) (Link opens in new window) J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30. PubMed PMID: 29602819; PubMed Central PMCID: PMC6910618.

Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Establishing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.(Link is external) (Link opens in new window) J Nucl Med. 2017 Nov;58(11):1786-1792. doi: 10.2967/jnumed.117.193359. Epub 2017 May 25. PubMed PMID: 28546332; PubMed Central PMCID: PMC6944167.

Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.(Link is external) (Link opens in new window) 2017;7(6):1589-1597. doi: 10.7150/thno.19050. eCollection 2017. PubMed PMID: 28529638; PubMed Central PMCID: PMC5436514.

Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, Lückerath K. [⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸F]FDG and laboratory values.(Link is external) (Link opens in new window) 2017;7(1):205-212. doi: 10.7150/thno.16576. eCollection 2017. PubMed PMID: 28042328; PubMed Central PMCID: PMC5196897.

Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E. Design, synthesis, and biological evaluation of CXCR4 ligands.(Link is external) (Link opens in new window) Org Biomol Chem. 2016 Nov 2;14(43):10298-10311. doi: 10.1039/c6ob01484d.PMID: 27752700

Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E. Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.(Link is external) (Link opens in new window)J Med Chem. 2016 Aug 25;59(16):7512-24. doi: 10.1021/acs.jmedchem.6b00566. Epub 2016 Aug 11.PMID: 27434274

Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, Lückerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester HJ, Knop S. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.(Link is external) (Link opens in new window) J Nucl Med. 2016 Feb;57(2):248-51. doi: 10.2967/jnumed.115.167361. Epub 2015 Nov 12. PubMed PMID: 26564323.

Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jörg G, Samnick S, Herrmann K, Buck AK, Einsele H, Lückerath K. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.(Link is external) (Link opens in new window) 2016;6(2):254-61. doi: 10.7150/thno.13921. eCollection 2016. PubMed PMID: 26877783; PubMed Central PMCID: PMC4729773.

Lückerath K, Lapa C, Albert C, Herrmann K, Jörg G, Samnick S, Einsele H, Knop S, Buck AK. 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.(Link is external) (Link opens in new window) 2015 Apr 10;6(10):8418-29. doi: 10.18632/oncotarget.3053. PubMed PMID: 25762625; PubMed Central PMCID: PMC4480763.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.(Link is external) (Link opens in new window) EMBO Mol Med. 2015 Apr;7(4):477-87. doi: 10.15252/emmm.201404698. PubMed PMID: 25736399; PubMed Central PMCID: PMC4403048.

Lückerath K, Kirkin V, Melzer IM, Thalheimer FB, Siele D, Milani W, Adler T, Aguilar-Pimentel A, Horsch M, Michel G, Beckers J, Busch DH, Ollert M, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Staal FJ, Rajalingam K, Hueber AO, Strobl LJ, Zimber-Strobl U, Zörnig M. Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain.(Link is external) (Link opens in new window) 2011 Jan 13;117(2):519-29. doi: 10.1182/blood-2010-07-292722. Epub 2010 Oct 22. PubMed PMID: 20971954.